Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,378.0
16.9 (0.50%)

 

  • STI Straits Times Index
    3,378.0
    16.9 (0.50%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,658.2
    9.3 (0.56%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,765.4
    303.7 (1.07%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,924.2
    23.0 (0.79%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,467.0
    420.8 (2.00%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,456.5
    53.2 (0.83%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,094.4
    27.8 (1.35%)
    Index delayed 20 minutes
  • XAO XAO
    6,786.2
    50.8 (0.75%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 951.8M
  • Value: 1,059.6M
  • Rise: 198
  • Fall: 120
  • Unch: 520

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Libra0.052+0.025
QT Vascular0.006+0.002
Sino Grandness0.050+0.004
SunMoonFood^0.063+0.005
Koh Eco0.058+0.001
G Invacom^0.137+0.005
Genting Sing0.920-
Sen Yue0.038-
Golden Agri-Res0.300-
TEE Intl0.102+0.001

World Indices

World Indices
Name Last Change
Nasdaq 8,146.5 -60.8
HSI 28,765.4 +303.7
HSCEI 10,909.4 +124.9
Jakarta 6,456.5 +53.2
Nikkei 225 21,467.0 +420.8
SSE Comp 2,924.2 +23.0
Shanghai A 3,062.8 +24.1
Shanghai B 290.0 +1.3
ShenZhen A 1,631.7 +12.2
ShenZhen B 972.3 +3.6
Taiwan W 10,873.2 +73.9
PSE Comp 0.0
KOSPI 2,094.4 +27.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NEUREN PHARMACEUTICALS LTD NEUREN PHARMACEUTICALS
Updated on 19 Jul 2019 (End of trading day)
Last (AUD): 1.410 Change: +0.030 High: 1.460 Remarks: -
Change (%): +2.17 Low: 1.360
Open 1.360 Yesterday's Close 1.38
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 100,090 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a 0.02979 Trailing EPS (AUD) e 0.02979 NAV (AUD) b 0.2391
PE a 47.331 Trailing PE f 47.338 Price / NAV b 5.8971
Dividend (AUD) d - Cash In Hand (AUD) g 0.2285 Issued & Paid-up Shares c 103,170,000
Dividend Yield (%) d - Price / Cash In Hand g 6.171 Treasury Shares h -
Beta - 75 Daysi -0.512 R-Squared - 75 Days(%)i 1.51 Market Cap (M) 145.470
Beta - 500 Daysi -4.651 R-Squared - 500 Days (%)i 0.18 Enterprise Value (M) 119.773
Piotroski F Score 5 Exchange Code NEU Par Value ( NZD ) n.a.
52 Weeks Volatility (%) 74.30 Free Float (%) 53.9
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 24 May 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 16 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NEUREN PHARMACEUTICALS LTD ASX 145.470 47.331 47.338 5.8971 -
Industry Biotechnology ASX 2,066.324 55.350 52.265 13.2121 0.961
Local Peer CSL ASX 101,856.584 45.649 41.810 14.7785 1.014
Local Peer POLYNOVO LIMITED ASX 1,087.490 - - 40.2200 -
Local Peer AVITA MEDICAL LTD ASX 814.015 - - 26.0479 -
Local Peer MESOBLAST LTD ASX 722.934 - - 1.0251 -
Local Peer NEXT SCIENCE LTD ASX 697.994 - - - -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 498.070 - - 10.3957 -
Local Peer TELIX PHARMACEUTIC ASX 363.579 - - 6.8716 -
Local Peer CYNATA THERAPEUTICS LTD ASX 177.280 - - 11.5846 -
Local Peer RESAPP HEALTH LIMITED ASX 107.920 - - 11.5672 -
Local Peer IMMUTEP LTD ASX 75.160 - - 2.2340 -
Local Peer ORTHOCELL LIMITED ASX 67.551 - - 25.1429 -
Local Peer PHYLOGICA LIMITED ASX 65.957 - - 7.1053 -
Other Local Peers IMUGENE LIMITED (ASX), ZELDA THERAPEUTICS LTD (ASX), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), RHINOMED LIMITED (ASX), MEMPHASYS LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), ADALTA LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), PATRYS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), BIONOMICS LTD (ASX), IMMURON LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), BIOXYNE LIMITED (ASX), BENITEC BIOPHARMA LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), ACTINOGEN MEDICAL LTD (ASX), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NOVITA HEALTHCARE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), MEDIBIO LIMITED (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Global Peer AMGEN INC NASDAQ 108,806.483 12.962 13.474 10.0449 3.055
Global Peer GILEAD SCIENCES INC NASDAQ 82,702.262 15.161 14.036 3.7676 3.534
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CELGENE CORP NASDAQ 63,614.452 15.723 13.407 7.7911 -
Global Peer BIOGEN INC NASDAQ 44,841.634 10.121 9.609 3.2424 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 44,598.350 21.274 20.697 9.4422 -
Global Peer ILLUMINA INC NASDAQ 43,100.400 52.180 50.647 10.8157 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,684.289 13.371 13.464 3.4606 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,087.830 349.072 65.052 2.7907 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 21,708.719 68.699 19.435 4.2359 0.873
Other Global Peers INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MODERNA INC (NASDAQ), 3SBIO (HKEx), Lonza (SGX), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), TILRAY INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ACCELERON PHARMA (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HAOHAI BIOTEC (HKEx), MOMENTA PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), FRONTAGE (HKEx), RETROPHIN INC (NASDAQ), VIVA BIOTECH (HKEx), KURA ONCOLOGY INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ASCLETIS-B (HKEx), WAVE LIFE SCIENCES LTD (NASDAQ), ARVINAS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), STOKE THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), OMEROS CORP (NASDAQ), MACROGENICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), PERSONALIS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), AVROBIO INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), SYNTHORX INC (NASDAQ), CKLIFE SCIENCES (HKEx), CYTOMX THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), ESSEX BIO-TECH (HKEx), KARYOPHARM THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), LEE'S PHARM (HKEx), PROTHENA CORP PLC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), RESTORBIO INC (NASDAQ), MERUS B V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), KADMON HLDGS INC (NYSE), SORRENTO THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SYNLOGIC INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), DPHARMA (Bursa), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), ATHERSYS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), MANNKIND CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CHIASMA INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AFFIMED N V (NASDAQ), CHIMERIX INC (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), NABRIVA THERAPEUTICS PLC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ENZO BIOCHEM INC (NYSE), SOLID BIOSCIENCES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ARDELYX INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), BBI LIFE SCI (HKEx), PFENEX INC (NYSE American), DYADIC INTERNATIONAL INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), IMV INC (NASDAQ), TOCAGEN INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), SESEN BIO INC (NASDAQ), BIOTIME INC (NYSE American), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NANTKWEST INC (NASDAQ), HEMISPHERX BIOPHARMA INC (NYSE American), UNI-BIO GROUP (HKEx), AVEO PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), VERASTEM INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), EQUILLIUM INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), TREVENA INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SAVARA INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), PORT (SET), ALPINE IMMUNE SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INFLARX N V (NASDAQ), OTONOMY INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CURIS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERMILLION INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), ORGENESIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), IBIO INC (NYSE American), COHBAR INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), OUTLOOK THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CEL-SCI CORP (NYSE American), ARAVIVE INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), REGENT PACIFIC (HKEx), AQUINOX PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), CT ENTERPRISE (HKEx), OPIANT PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VACCINEX INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), EVOGENE LTD (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CONTRAFECT CORP (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), SENESTECH INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), EXTRAWELL PHAR (HKEx), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), AETERNA ZENTARIS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), AZURRX BIOPHARMA INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CO DIAGNOSTICS INC (NASDAQ), HISTOGENICS CORP (NASDAQ), PRECIPIO INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), VICAL INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), NANOVIRICIDES INC (NYSE American), OHR PHARMACEUTICAL INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ATYR PHARMA INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), TROVAGENE INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), CONATUS PHARMACEUTICALS INC (NASDAQ), Suntar Eco-City^ (SGX), ADVAXIS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), QT Vascular (SGX), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), HAO WEN HLDGS (HKEx), MGRC (Bursa), MEGASUN (Bursa), NEURALSTEM INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days -+0.235
+20.00 %
20 Days -+0.240
+20.51 %
Medium Term Return 3 Months -+0.280
+24.78 %
6 Months -+0.030
+2.17 %
1 Year --1.330
-48.54 %
Long Term Return 2 Years -+0.190
+15.57 %
3 Years -+0.290
+25.89 %
5 Years --0.590
-29.50 %
Annualised Return Annualised --
-6.75 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.980 - 2.890 Change From 1 Year Low +0.430 % Change From 1 Year Low (%) +43.88
Change From 1 Year High -1.480 % Change From 1 Year High (%) -51.21
2 Years Range 0.155 - 3.600 Change From 2 Years Low +1.255 % Change From 2 Years Low (%) +809.68
Change From 2 Years High -2.190 % Change From 2 Years High (%) -60.83
5 Years Range 0.155 - 3.700 Change From 5 Years Low +1.255 % Change From 5 Years Low (%) +809.68
Change From 5 Years High -2.290 % Change From 5 Years High (%) -61.89
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. The company was founded on December 17, 2001 and is headquartered in Melbourne, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Jul 2019 1.360 1.460 1.360 1.410 100,090 -
18 Jul 2019 1.340 1.425 1.290 1.380 89,037 -
17 Jul 2019 1.425 1.425 1.285 1.330 134,788 -
16 Jul 2019 1.420 1.450 1.410 1.430 11,595 -
15 Jul 2019 1.400 1.470 1.400 1.450 94,867 -
12 Jul 2019 1.370 1.415 1.325 1.410 80,623 -
11 Jul 2019 1.380 1.400 1.360 1.380 72,884 -
10 Jul 2019 1.290 1.385 1.280 1.385 326,525 -
09 Jul 2019 1.175 1.285 1.150 1.280 73,599 -
08 Jul 2019 1.150 1.175 1.150 1.175 25,425 -
05 Jul 2019 1.160 1.175 1.135 1.175 115,196 -
04 Jul 2019 1.130 1.140 1.120 1.140 28,731 -
03 Jul 2019 1.135 1.135 1.115 1.130 43,111 -
02 Jul 2019 1.150 1.155 1.120 1.135 22,155 -
01 Jul 2019 1.145 1.160 1.140 1.160 55,002 -
28 Jun 2019 1.120 1.145 1.100 1.145 104,659 -
27 Jun 2019 1.115 1.120 1.110 1.110 47,055 -
26 Jun 2019 1.140 1.140 1.100 1.120 74,252 -
25 Jun 2019 1.140 1.150 1.125 1.130 20,208 -
24 Jun 2019 1.170 1.170 1.135 1.140 36,626 -
21 Jun 2019 1.110 1.170 1.110 1.170 51,381 -
20 Jun 2019 1.140 1.140 1.110 1.110 33,916 -
Summary
Current 2 Weeks
(08 Jul 2019 to 19 Jul 2019)
1.150 1.470 1.150 1.410 1,009,433 -
Previous 2 Weeks
(24 Jun 2019 to 05 Jul 2019)
1.170 1.470 1.135 1.175 546,995 -
4 Weeks from
(24 May 2019 to 21 Jun 2019)
1.195 1.470 1.150 1.170 1,215,785 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.